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Objective: Genome-wide association studies (GWAS) have been successful at identifying associations with stroke and
stroke subtypes, but have not yet identified any associations solely with small vessel stroke (SVS). SVS comprises one
quarter of all ischemic stroke and is a major manifestation of cerebral small vessel disease, the primary cause of vas-
cular cognitive impairment. Studies across neurological traits have shown that younger-onset cases have an increased
genetic burden. We leveraged this increased genetic burden by performing an age-at-onset informed GWAS meta-
analysis, including a large younger-onset SVS population, to identify novel associations with stroke.
Methods: We used a three-stage age-at-onset informed GWAS to identify novel genetic variants associated with
stroke. On identifying a novel locus associated with SVS, we assessed its influence on other small vessel disease phe-
notypes, as well as on messenger RNA (mRNA) expression of nearby genes, and on DNA methylation of nearby
CpG sites in whole blood and in the fetal brain.
Results: We identified an association with SVS in 4,203 cases and 50,728 controls on chromosome 16q24.2 (odds
ratio [OR; 95% confidence interval {CI}]51.16 [1.10–1.22]; p5 3.231029). The lead single-nucleotide polymorphism
(rs12445022) was also associated with cerebral white matter hyperintensities (OR [95% CI]5 1.10 [1.05–1.16];
p5 5.33 1025; N5 3,670), but not intracerebral hemorrhage (OR [95% CI]50.97 [0.84–1.12]; p5 0.71; 1,545 cases,
1,481 controls). rs12445022 is associated with mRNA expression of ZCCHC14 in arterial tissues (p59.431027) and
DNA methylation at probe cg16596957 in whole blood (p55.33 1026).
Interpretation: 16q24.2 is associated with SVS. Associations of the locus with expression of ZCCHC14 and DNA
methylation suggest the locus acts through changes to regulatory elements.
ANN NEUROL 2017;81:383–394
Genome-wide association studies (GWAS) enableidentification of common genetic variants that
influence disease risk and have proved successful in eluci-
dating pathophysiological mechanisms underlying diseases
with a genetic influence.1 A number of GWAS associa-
tions have recently been identified with ischemic stroke,
almost all of which have been associated with specific
stroke subtypes.2–4 A number of genetic associations have
been reported with cardioembolic (CE) and large artery
stroke (LAS), but, in contrast, there have been no robust
associations solely with small vessel stroke (SVS). This is
despite epidemiological data that suggest genetic factors
are particularity important for SVS. For example, there
are a number of monogenic stroke disorders associated
with SVS,5 and family history studies have shown a strong
association between SVS and a family history of stroke.6
Similarly, related traits, including white matter hyperinten-
sities (WMH), have been shown to have high heritability.7
SVS itself comprises one quarter of all ischaemic
stroke and is one of the clinically overt manifestations of
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cerebral small vessel disease (SVD), the major cause of
vascular cognitive impairment. Other radiological features
of SVD include WMH, best observed on T2-weighted
magnetic resonance imaging (MRI), cerebral micro-
bleeds—observed on gradient echo MRI, and intracere-
bral hemorrhages (ICH).8 Despite its importance, the
pathogenesis of SVD remains poorly understood and this
limits the development of proven treatments for estab-
lished disease.
One consistent finding across adult-onset neurologi-
cal complex diseases, including Parkinson’s disease,9 Alz-
heimer’s disease,10 and stroke,11 is that younger onset
cases have a stronger genetic burden from common
disease-associated single-nucleotide polymorphisms
(SNPs). Leveraging this increased burden, by focussing on
younger-onset cases in analysis of genetic data, can lead to
detection of novel trait-associated variants.11 This may be
particularly relevant for SVS, given that epidemiological
studies have shown stronger associations with SVS and a
family history of stroke in younger stroke cases.6
Here, we perform an age-at-onset informed GWAS
meta-analysis in stroke, including a large population of
younger-onset (age< 70) SVS cases. We perform analysis
for all ischemic stroke (IS) and its three subtypes: CE,
LAS, and SVS. Using this approach, we identify a novel
association with SVS, seek further validation of the locus
in other SVD phenotypes, and assess the influence of
SNPs at the locus on messenger RNA (mRNA) expres-
sion of nearby genes and DNA methylation at nearby
CpG sites.
Materials and Methods
Study Design
We used a three-stage design for the association analysis
(Fig 1). In brief, in stage I, we performed association analysis of
stroke phenotypes in 10,210 cases and 12,285 controls of Euro-
pean ancestry from Europe, United States, and Australia; most
of which contributed to the METASTROKE ischaemic stoke
GWAS meta-analysis—and all of which have been described
previously (Table 1).2,12,13 In all cases, diagnosis of stroke was
FIGURE 1: Flow chart of analyses performed. GTEx5Genotype-Tissue Expression; mRNA5messenger RNA; SNP5 single-
nucleotide polymorphism; SVS5 small vessel stroke; [Color figure can be viewed at wileyonlinelibrary.com]
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based on clinical evaluation with radiological confirmation.
Subtyping of stroke cases was based on the TOAST criteria; in
this analysis, we considered the CE, LAS, and SVS subtypes.14
Of note, our SVS analysis included a large sample (1,012 cases,
970 controls) of younger-onset (age< 70) MRI-confirmed lacu-
nar strokes, meaning that, although we investigated all subtypes,
we had most power to identify associations with SVS.
In stage II, we took three SNPs from the top 25 loci from
each phenotype forward for a first in silico replication in the
NINDS Stroke Genetics Network (SiGN),2 which consisted of
7,743 cases and 17,790 controls. We meta-analyzed stages I and II
together and identified three loci with p< 53 1027. Finally, in
stage III, we determined whether these three SNPs were associated
with the phenotype in which they were identified (CE or SVS) by
in silico replication in a large Icelandic population (deCODE; 520
SVS cases, 1,100 CE cases, 50,728 controls; stage III).
Genotyping and Imputation
Genotyping, quality control, and imputation of all studies has
been described previously.2,3,13 All studies were genotyped on
commercially available arrays from Illumina (San Diego, CA)
or Affymetrix (Santa Clara, CA) and imputed to 1000
Genomes phase 1 reference panels using IMPUTE or
MACH.15 Imputation quality score was assessed by calculating
the ratio of the observed to the expected binomial variance of
the allele dosage.
Association Analysis
Association analysis was performed using a covariate-informed
approach,11,16 which we, and others, have implemented previ-
ously.11,17 Briefly, the approach uses case/control status and a
covariable—in this case, age-at-onset—to estimate each individ-
ual’s stroke liability, which can be interpreted as their underly-
ing propensity to stroke, on a normally distributed scale. In this
analysis, cases with an earlier age-at-onset take more-extreme
positive values than late-onset cases given that, attributed to the
lower prevalence of stroke at younger ages, they are assumed to
have higher stroke liability. Conversely, controls who are older
and stroke free at age-at-observation take more-extreme negative
value than younger controls given that they have been stroke
TABLE 1. Ischemic Stroke Study Participants
Population IS CE LAS SVS Controls % Cases
With MRI
Age of Cases
(mean (SD))
Stage I populations
ASGC 1,162 240 421 310 1,244 43.0 72.9 (13.2)
WTCCC2-Germany 1,174 330 346 106 797 83.0 66.7 (12.9)
WTCCC2-UK 2,374 474 498 460 5,175 37.2 72.2 (12.5)
Milano 366 64 73 25 407 86.7 57.4 (15.6)
DNA-lacunar/GENESIS 1,287 80 64 1,012 970 100.0 59.6 (12.0)
LSS 455 157 70 55 455 89.0 67.7 (14.5)
ISGS/SWISS 1,014 235 217 187 1,370 83.0 66.5 (13.6)
BRAINS 361 29 120 97 444 30.8 74.4 (14.2)
MGH-GASROS 294 106 68 23 376 60.0 66.7 (14.5)
VISP 1,723 — — — 1,047 47.0 68.0 (10.7)
Total (discovery) 10,210 1,715 1,877 2,275 12,285
Stage II populations
NINDS Stroke Genetics
Network
7,743 2,001 1,130 1,408 17,970 62.0 66.3 (14.8)
Stage III populations
deCODE — 1,100 — 520 20,473 NA 72.7 (11.6)
Total 17,953 4,816 3,007 4,203 50,728
IS5 all ischemic stroke; CE5 cardioembolic stroke; LAS5 large artery stroke; SVS5 small vessel stroke; ASGC5Australian Stroke Genetics Col-
laborative; WTCCC25Wellcome Trust Case Control Consortium 2; LSS5 Leuven Stroke Study; BRAINS5Bio-repository of DNA in stroke;
MGH-GASROS5The MGH Genes Affecting Stroke Risk and Outcome Study; VISP5The Vitamin Intervention for Stroke Prevention Trial;
NA5 information not available.
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free for a longer time and are therefore assumed to have a lower
stroke liability.
In this analysis, the approach was implemented in our
software, CIAO (provided at https://sites.google.com/site/mtray-
lor263/software/covariate-informed-gwas-analysis). Specifically,
the approach taken is to model phenotype data using a contin-
uous unobserved normally distributed quantitative trait, called
the disease liability (u5
PJ
j51 cjðtj2tj Þ1m1e), where e5cg1
N ð0; 1Þ and g denotes the genetic effects. Then, an individual
is a case (z5 1) if and only if u  0 and is a control (z5 0)
otherwise. cj is a parameter estimating the effect of a given
covariate j on the liability scale. m denotes the disease preva-
lence p at the covariate mean tj under a normal cumulative dis-
tribution function

Uð2mÞ5p

. This model is used to
approximate the effect of a disease covariate—in this case, age-
at-onset—on the liability scale, based on estimates of risk of IS
by age from epidemiological data, thereby estimating cj . For
this analysis, the sex-specific risk of IS by age from an index
age of 55 was obtained from population-based estimates (1.8%,
5.4%, and 12.1% before 65, 75, and 85, respectively, in wom-
en; 2.4%, 7.3%, and 12.6% before 65, 75, and 85, respectively,
in men).18 We assumed that 20% of IS cases had each of the
cardioembolic, small vessel, or large vessel stroke subtypes,
approximating proportions observed in population-based stud-
ies.19 We developed two models for our analysis; one based on
the risk rates for all IS and, second, for the three stroke sub-
types. We used these models to calculate posterior mean liabili-
ties after conditioning on age-at-onset for the four stroke
phenotypes separately (Eðejz; tÞ5
Ð1
2cðt2t Þ2m e
1ﬃﬃﬃ
2p
p e
2e2
2ð Þde
Ð1
2cðt2t Þ2m
1ﬃﬃﬃ
2p
p e
2e2
2ð Þde
; if z51).
Controls were modeled in the same way, but were assumed to
take the posterior mean from the lower (unaffected) portion of
the distribution in the liability threshold model
(Eðejz; tÞ5
Ð 2cðt2t Þ2m
1 e
1ﬃﬃﬃ
2p
p e
2e2
2ð ÞdeÐ 2cðt2t Þ2m
1
1ﬃﬃﬃ
2p
p e
2e2
2ð Þde
; if z50Þ. Where age data was
missing, individuals were assigned the median age value (<1%
of cases). Regression was then performed on posterior liabilities
(Eðejz; tÞÞ by multiplying the number of samples by the
squared correlation between the expected genotype dosage and
posterior mean liabilities for each of the discovery cohorts in
the four IS phenotypes (all IS, CE, LAS, and SVS). Ancestry-
informative principal components were included, where appro-
priate, using the EIGENSTRAT procedure.20 Any residual
inflation was accounted for by adjusting results by the genomic
inflation factor, k.21 In all analyses, SNPs with imputation qual-
ity score <0.7 or minor allele frequency (MAF)< 0.01 were
excluded and meta-analysis was performed using Stouffer’s
method in METAL.22
Further Analysis of a Novel Locus Associated
With SVS
For a novel variant associated with SVS, we performed further
analysis to elucidate the association for different groups based
on age-at-onset. First, for data sets in stage I and II, we divided
the cases into quartiles based on age-at-onset and estimated the
association of the SNP with each quartile using logistic regres-
sion with all controls, meta-analyzing using a fixed-effects
inverse variance weighted approach (data not available in
BRAINS, MGH-GASROS, and ISGS/SWISS). Second, we
interrogated associations at the locus in non-European ancestry
populations, comprising 657 small vessel African-American
stroke cases and 3,251 matched controls from the NINDS
Stroke Genetics Network and African or African-Caribbean
ancestry individuals from the South London Ethnicity and
Stroke Study (SLESS),2,23 and 314 SVS cases and 5,193 con-
trols of Pakistani ancestry from the RACE study.3 We used
logistic regression to evaluate the association within each group
and evaluated the overall transethnic association by meta-
analyzing using Stouffer’s method.
In addition, we explored the association of the SNP with
other SVD phenotypes. We evaluated association of the SNP
with (1) white matter hyperintensity volumes (WMHV) mea-
sured on T2-weighted MRI in 3,670 IS patients of European
ancestry24; (2) in MRI-defined small subcortical brain infarcts
(SSBI) brain infarcts in 17,197 transethnic individuals (85.7%
European; 8.8% African-American; 3.5% Hispanic; 1.0% Chi-
nese; and 1.0% Malay) from community studies recruited with-
in the neuro-CHARGE consortium (mean age, 68.906 10.31;
1,986 with infarcts). SSBI were defined as MRI-defined brain
infarcts of 3 to 15 or 3 to 20mm in size, located in the basal
ganglia, the white matter, or the brainstem. Association analysis
was performed overall, and for the subset of cases with extensive
WMH burden—defined as the top age-specific quartile of
WMHV on a quantitative scale or above the age-specific medi-
an by 5-year age categories for studies using semiquantitative
measurements of WMH burden; N5 549; and (3) ICH in
1,545 European ancestry cases and 1,481 controls, described
previously,25 and stratified according to lobar or nonlobar
location.
Evaluation of Regulatory Chromatin States,
mRNA Expression, and DNA Methylation
To investigate a novel locus, we used existing resources and per-
formed some further analyses to characterize its regulatory
potential. We interrogated chromatin states and regulatory
motifs from ENCODE and Epigenomics Roadmap using Hap-
loreg v4.1.26 We also evaluated whether the associated SNP
influences gene expression using the Genotype-Tissue Expres-
sion (GTEx) portal.27 Upon identifying an association between
the SNP and expression of a nearby gene, we evaluated the evi-
dence that the association signal for SVS and gene expression
derives from the same causal variant using a Bayesian colocali-
zation test.28 Using the R coloc package (http://cran.r-project.
org/web/packages/coloc), we compared five models for SNPs
with 50kb of our lead SNP using the approach (H0: No associ-
ation with either trait; H1: Association with SVS, not with
expression; H2: Association with expression, not with SVS; H3:
Association with SVS and expression, two independent SNPs;
H4: Association with SVS and expression, one shared SNP).
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Next, we assessed whether the lead SNP (rs12445022), or
three SNPs in linkage disequilibrium (LD; rs4843625,
rs12920915, and rs12444224), influence DNA methylation lev-
els in whole blood. We evaluated genetic associations of whole-
blood DNA methylation levels at selected CpG sites profiled
on the Illumina Infinium HumanMethylation450 BeadChip
array in a group of 660 monozygotic (MZ) female twins (mean
age, 59; age range, 18–79). These individuals were research vol-
unteers from the TwinsUK cohort in the United Kingdom.29
All were of European ancestry. For each CpG site of interest,
we calculated the normalized methylation means for the 330
MZ twin pairs as a phenotype in the genetic analysis and took
into account covariates, including smoking, body mas index,
age, methylation plate, and blood-cell count estimates. Twin-
sUK imputed genotypes were obtained for the 1000 Genomes
reference set,30 where we excluded SNPs with Hardy–Weinberg
p< 13 1024, MAF< 5%, and those with IMPUTE info value
<0.8. We tested for association with our SNP, or SNPs in close
LD (r2> 0.6) with DNA methylation at CpG sites. We used
p< 43 1025, equivalent to a false discovery rate
(FDR)< 5%,31 to identify significant cis-mQTL associations.
Finally, we explored genetic associations at 16q24.2
(defined as within 50kb of rs12445022) with DNA methylation
profiles in 166 human fetal brain samples (92 male, 74 female)
ranging from 56 to 166 days postconception initially using
publically available data—which hold results for mQTL associa-
tions reaching the study-wide significance threshold (http://epi-
genetics.essex.ac.uk/mQTL/). Methods for this study have been
published in detail elsewhere.32 Briefly, DNA methylation levels
were profiled on the Illumina Infinium HumanMethylation450
BeadChip array and SNP genotypes were obtained from the
Illumina HumanOmniExpress BeadChip and imputed to 1000
Genomes phase 3 using SHAPEIT and Minimac3 through the
Michigan Imputation Server.15,33 SNP-methylation probe pairs
were tested using the R package, MatrixEQTL,34 including
covariates to control for age, sex, and ancestry-informative prin-
cipal components. Upon identifying a significant association at
16q24.2, we performed additional analyses (not publicly avail-
able: we gained access to the data) to test whether any of our
four SNPs (rs12445022, rs4843625, rs12920915, and
rs12444224) were associated with methylation at the identified
probe. We again used p< 43 1025, equivalent to an FDR
<5%,31 to identify significant cis-mQTL associations.
Results
Association Analysis
In phase I association analysis, we confirmed previous
associations between HDAC9 and LAS (rs2107595,
p5 3.03 1028) and between PITX2 and CE
(rs192172299, p5 2.03 1029).3,4 Previous associations
between ZFHX3 and CE and between MMP12 and LAS
did not reach genome-wide significance in this analysis
(rs879324, p5 5.03 1027 and rs586701, p5 0.0014,
respectively).11 An SNP in a region close to HABP2
previously associated with young-onset IS was also
significant, albeit not genome wide, in this analysis
(rs11196288; p5 2.43 1024).35 Genomic inflation k
and the equivalent values, scaled to 1,000 cases and
1,000 controls (k1000),
36 were well controlled across all
analyses (IS, k (k1000)5 1.05 (1.00); CE, k
(k1000)5 1.02 (1.00); LAS, k (k1000)5 1.02 (1.00); SVS.
k (k1000)5 1.01 (1.00)).
We took 25 independent loci forward (three SNPs
in LD from each locus selected on p value) from each
analysis (IS, CE, LAS, and SVS) for in silico replication
in the NINDS Stroke Genetics Network study (stage II).
Information on these SNPs is provided in Supplementary
Tables 1 to 4. Following this analysis, excluding previous-
ly reported associations, three loci showed significance at
p< 53 1027 (two with SVS, one with CE) and one was
genome-wide significant (rs12445022, p5 4.43 1028,
associated with SVS). We followed up all three loci in a
second in silico replication (stage III) in a large Icelandic
population (deCODE). A single SNP, rs12445022,
showed evidence of replication (p5 0.011). When per-
forming a meta-analysis across all populations,
rs12445022 was associated with SVS at genome-wide sig-
nificance (p5 3.23 1029; Fig 2). The SNP was either
genotyped or well imputed (info> 0.9) in all cohorts
and lies in an intergenic region between junctophilin 3
(JPH3) and zinc finger CCHC domain-containing 14
(ZCCHC14). To confirm the association with
rs12445022, we repeated the analysis using logistic
regression, the approach taken in a conventional GWAS.
The association was validated using this method, and
associations were consistent across populations (odds
ratio [OR; 95% confidence interval {CI}]5 1.16 [1.10–
1.22]; p5 1.33 1028; heterogeneity, p5 0.56; Fig 3).
Further Analysis of a 16q24.2 Novel Locus
Associated With SVS
We evaluated association of the lead SNP in different
quantiles of age at stroke onset, using all controls in each
analysis. The strongest associations were observed in
younger-onset cases, suggesting that the influence of the
SNP might be greatest in these individuals (Fig 4). How-
ever, this was not demonstrated statistically (p> 0.05).
We performed further analysis to assess whether the
SVS-associated SNP influenced other manifestations of
cerebral SVD. The SNP (rs12445022) was also associat-
ed with increased T2-WMHV (OR [95% CI]5 1.10
[1.05–1.16]; p5 5.33 1025; Figs 2 and 5) and showed
little heterogeneity across study groups (heterogeneity,
p5 0.58). Conversely, the SNP was not associated with
ICH—neither overall, nor in subgroups divided by
lobar/nonlobar location. For SSBI, the direction of effect
was the same as for SVS, but the effect was weaker and
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nonsignificant (OR [95% CI]5 1.05 [0.97–1.14];
p5 0.28). For the subgroup with WMH, the effect was
stronger—and similar to that observed for SVS, but was
again nonsignificant (OR [95% CI]5 1.15 [0.99–1.33];
p5 0.076).
We next evaluated the identified locus in non-
European ancestry populations. The SNP had a similar
frequency to Europeans in South Asians from RACE
(MAF5 37%), but was rarer in African ancestry popula-
tions, consisting of African Americans from the NINDS
Stroke Genetics Network and United Kingdom individu-
als of African or African-Caribbean ethnicity from SLESS
(MAF5 14%). Associations with the SNP were in the
same direction as in European ancestry populations
(Fig 4), but did not reach statistical significance in either
ancestry, reflecting the much smaller sample sizes.
However, when combining data from all populations,
evidence for association at the SNP (p5 1.43 1029) was
stronger than in European ancestry populations alone,
which might suggest a common association across popu-
lations. Indeed, there was no evidence of a significant
difference in the strength of association between
the European and non-European ancestry individuals
(p5 0.64).
Regulatory Chromatin States, mRNA
Expression, and DNA Methylation
Related to 16q24.2
We used existing databases to assess the functional conse-
quences of SNPs in the 16q24.2 region. First, we used
FIGURE 2: Associations at 16q24.2 with (A) small vessel stroke, (B) cerebral white matter hyperintensities, (C) mRNA expression
of ZCCHC14, and (D) gene locations and associations of the locus with DNA methylation. mRNA5messenger RNA; SVS5 small
vessel stroke; WMH5white matter hyperintensities; ZCCHC145 zinc finger CCHC domain-containing 14; JPH35 junctophilin
3; meQTL5methylation quantitative trait locus. [Color figure can be viewed at wileyonlinelibrary.com]
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the Haploreg v4.1 database to interrogate chromatin
states and regulatory motifs from ENCODE and the
NIH Roadmap Epigenomics Mapping Consor-
tium.26,37,38 The database showed that our lead SNP
influences chromatin states in multiple tissues. The SNP
is classified as a genic promoter in nine tissues, an
enhancer in 13 tissues, and overlaps DNAse1 hypersensi-
tivity sites in 21 tissues.
Second, we used publicly available databases to
evaluate the evidence that the lead SNP influences
expression of nearby genes using the GTEx portal.27 The
implicated A allele of our lead SNP (rs12445022) was
associated with decreased expression of ZCCHC14 in tib-
ial arterial tissue (p5 9.43 1027; Fig 2). We used a
Bayesian colocalization technique to assess whether the
same variant drives the both the SVS association signal
and mRNA expression of ZCCHC14.28 There was over-
whelming evidence in support of H4 (posterior proba-
bility5 99.7%), strongly indicating that a single
variant—most likely to be rs12445022—influences both
SVS and expression of ZCCHC14.
Finally, we performed analyses to assess whether the
lead SNP, or the three SNPs in LD, influence DNA
methylation at CpG probes in whole blood. We found
evidence that the lead SNP, and three SNPs in close LD
(r2> 0.6), influence DNA methylation at 4 nearby CpG
sites (cg16596957, cg10312981, cg03020503, and
cg00555085; all p< 4.03 1025; Table 2). The implicat-
ed A allele of rs12445022 was associated with decreased
methylation at the cg16596957 probe (beta [standard
error; SE]5 –0.38 [0.082]; p5 5.33 1026). The SNPs
explained between 5% and 8% of the methylation vari-
ance at the given CpG sites. The same 16q24.2 region
by CpG probe (cg16596957) association was also recent-
ly reported in another study in whole blood.40 In addi-
tion, we looked for an association between SNPs at the
16q24.2 locus and DNA methylation levels in fetal
brains, initially using publicly available data (http://epige-
netics.essex.ac.uk/mQTL/). There was a strong associa-
tion with SNPs in distant LD with our lead SNP
FIGURE 3: Forest plot of associations with rs12445022
under a logistic regression model. CI5 confidence interval.
[Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4: Association of rs12445022 with small vessel
stroke by quartiles of age-at-stroke onset in Europeans.
CI5 confidence interval.
FIGURE 5: Associations with rs12445022 for stroke and
cerebral small vessel disease phenotypes. CI5 confidence
interval; IS5 all ischemic stroke; WMH5white matter
hyperintensities.
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(rs8047314  cg08031982; p5 7.13 10214; r25 0.16
with rs12445022). We then performed additional analy-
ses (not publicly available: we gained access to the data)
to test whether our lead SNP, or the SNPs in close LD,
were associated with methylation at cg08031982. We
could identify no associations that reached our signifi-
cance threshold (p< 4.03 1025). However, there was a
near-significant association of rs12920915 and
rs4843625 with methylation at the cg08031982 probe
(both p5 7.83 1025). Our lead SNP, rs12445022, was
not associated (p5 9.93 1024).
Discussion
Genome-wide association studies in SVS have largely
been disappointing. Some studies have suggested that an
association with all IS at the highly pleiotropic 12q24.12
is driven by an association with SVS,2 but no genome-
wide significant associations specifically with SVS have
yet been identified. Using an age-of–onset informed anal-
ysis approach, we identified a novel locus at 16q24.2
associated with SVS. The SNP was also associated using
a standard logistic regression approach, but was less sig-
nificant—a difference of almost an order of magnitude
(p5 3.23 1029 compared to p5 1.33 1028). In addi-
tion, the association was stronger with younger-onset
SVS, suggesting a greater influence in these individuals.
We tested whether the 16q24.2 association extends to
other cerebral SVD-related phenotypes. We showed that
the same locus also influences WMH and may have a
similar effect on MRI-defined subcortical brain infarcts
from prospective studies, although the association did
not reach significance in our analysis. However, the locus
does not appear to influence risk of ICH. A SNP in the
same 16q24.2 region (rs4081947), in partial LD with
our SNP (r25 0.28), was also recently reported to be
associated with migraine in a large GWAS meta-analy-
sis.41 These data provide strong supportive evidence that
this 16q24.2 locus harbors variants that influence diseases
of the cerebral vasculature.
Identifying the mechanisms by which GWAS asso-
ciations influence disease risk presents additional chal-
lenges. In this case, the underlying mechanism and the
specific genes implicated remains uncertain. Interrogation
of mRNA expression data points to the lead SNP
influencing expression of the nearest gene, ZCCHC14.
This gene is ubiquitously expressed, but is highly
expressed in arterial tissues and in the brain. However, its
function is not well characterized. Zinc fingers of the
CCHC-type contain an 18-digit residue found in the
nucleocapsid of retroviruses and therefore may be impor-
tant in viral response. Other plausible candidate genes
reside nearby. The locus lies around 1Mb away from
TABLE 2. Significant Associations Between rs12445022 and LD SNPs (r2>0.6) With cis-Methylation Probes in
Whole Blood
SNP Variant SNP BP CpG Probe Probe BP RA Beta (SE) r2 p
rs12445022 87,575,332 cg16596957 87,575,151 A –0.38 (0.082) 0.058 5.33 1026
rs4843625 87,576,996 cg16596957 87,575,151 C –0.33 (0.075) 0.053 1.33 1025
rs4843625 87,576,996 cg10312981 87,577,304 C 0.39 (0.074) 0.077 1.93 1027
rs4843625 87,576,996 cg03020503 87,577,656 C 0.35 (0.075) 0.059 5.03 1026
rs4843625 87,576,996 cg00555085 87,616,248 C 0.34 (0.075) 0.057 6.63 1026
rs12920915 87,577,521 cg16596957 87,575,151 T -0.38 (0.075) 0.069 7.33 1027
rs12920915 87,577,521 cg10312981 87,577,304 T 0.38 (0.075) 0.068 1.03 1026
rs12920915 87,577,521 cg03020503 87,577,656 T 0.34 (0.076) 0.055 1.13 1025
rs12920915 87,577,521 cg00555085 87,616,248 T 0.33 (0.076) 0.051 2.23 1025
rs12444224 87,580,855 cg16596957 87,575,151 T –0.38 (0.075) 0.068 8.03 1027
rs12444224 87,580,855 cg10312981 87,577,304 T 0.38 (0.075) 0.069 8.73 1027
rs12444224 87,580,855 cg03020503 87,577,656 T 0.35 (0.076) 0.054 1.13 1025
rs12444224 87,580,855 cg00555085 87,616,248 T 0.32 (0.076) 0.050 2.63 1025
SNP5 single-nucleotide polymorphism; BP5 base position; RA5 reference allele; SE5 standard error; r25 proportion of methylation variance
explained by respective genotype.
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genes encoding forkhead box proteins, including FOXC2,
FOXL1, and FOXF1. These proteins, particularly the
closely related FOXC1—a paralogue of FOXC2, have
been implicated in Mendelian forms of SVS.42 We found
no evidence linking our SNP to expression of these
genes. However, the function of these proteins changes
dramatically between early development and in adult tis-
sues,43 which might explain the absence of an associa-
tion. This, coupled with the fact that FOXF2 variants
have also recently been implicated in IS,44 make fork-
head box proteins exciting targets for follow-up
experiments.
Assessing DNA methylation, the process by which
methyl groups are added to DNA thereby modifying its
function, offers another potential method for mechanisti-
cinsight. This epigenetic process influences gene expres-
sion and regulation in humans, and may be particularly
relevant for diseases, such as stroke, where gene-
environment interactions are likely to play an important
role in pathogenesis.45 Substantial interindividual varia-
tion exists with respect to age and tissue type.46 Howev-
er, an important emerging mechanism influencing
methylation is local sequence content.47 Notably, recent
studies have shown that GWAS findings from stroke-
relevant traits, such as blood pressure, are likely to act by
influencing DNA methylation.48 This may be particular-
ly relevant for SVS, in which environmental and other
vascular risk factors, such as hypertension, are important
and have been shown to interact with disease risk.49 We
evaluated whether our associated SNP (rs12445022), or
SNPs in close LD, influence methylation of nearby CpG
sites. We found evidence from whole blood that the
same genetic variation influences DNA methylation.
SNPs in distant LD also influenced DNA methylation at
a different probe (cg08031982) in the fetal brain. Fur-
ther evidence comes from published studies in lung,
breast, and kidney tissues,31 as well as in utero,50 all of
which have shown that the genetic variation at the same
16q24.2 region influences methylation at the
cg08031982 probe. Interestingly, the CpG sites influ-
enced by the locus appear to differ by tissue, with differ-
ent probes affected in whole blood compared to fetal
brain. This might imply tissue-specific functional conse-
quences of the locus and therefore highlights the impor-
tance of performing follow-up experiments in
appropriate tissues. Based on the evidence presented here,
we can only speculate on how genetic variation at the
locus leads to increased risk of SVS. One hypothesis is
that expression of ZCCHC14, or other proteins, is medi-
ated through altered methylation of the probes identified.
This might occur, in part, in response to environmental
stimuli. Evaluating these hypotheses in a relevant tissue
type will be an important future analysis to identify the
causal mechanisms leading to SVS.
This study has limitations. Our results suggested
that the association may be present in other ethnicities,
but we had an insufficient number of cases to establish
common risk conclusively. Follow-up studies are there-
fore required in other ethnic groups. In addition, down-
stream functional experiments will be required to
determine the consequences of the identified association.
The mRNA expression and methylation analyses pre-
sented herein were constrained by available tissue types.
Validation of the findings in more disease-relevant tissue
types, such as cerebral small vessels, therefore represent
important follow-up analyses, although obtaining such
tissue in a state to allow mRNA studies is very challeng-
ing. We performed mRNA expression and methylation
analyses using either the lead SNP (rs12445022) or three
LD SNPs. The results should be interpreted with the
limitation that we cannot be certain that any of these
SNPs is the causal variant. Radiological confirmation of
SVS in this study was performed using either computed
tomography or MRI. Evidence shows that MRI is con-
siderably more reliable at identifying SVS. Replication of
the association in an MRI-confirmed population may
therefore provide a more-accurate estimate of the effect
of the locus on SVS risk. Similarly, interrogation of caus-
ative classification system definitions of SVS may provide
further insights.51 Another method of interrogating the
combined influence of age and genotype is by testing for
an interaction. In this analysis, we were unable to do this
because age was not available in some sets of controls
(eg, WTCCC2).
In this large genome-wide meta-analysis using an
age-at-onset informed approach, we have identified the
first genome-wide significant locus that is associated sole-
ly with SVS. Our findings, which point to subtle changes
in gene expression and DNA methylation influencing
disease risk, show that strategies that account for different
liability across disease-related covariates, such as age, can
identify novel associations with disease.
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